Consensus Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
73.1 USD +2.57% Intraday chart for Ligand Pharmaceuticals Incorporated +0.19% +2.35%

Evolution of the average Target Price on Ligand Pharmaceuticals Incorporated

Price target over the last 5 years

History of analyst recommendation changes

7f0769f512fc.60VO8TiUuqy1WjuCIpQxcTfCJwkRlMZLg0Pqy1e-7RM.rSJ2vnnZ18-DL2v4W-VgGAeNQEhW378vxRagnz_H1XeSDgSkbuSLx-8VYg~c305f586159f2ebd9a5ab811a8b3901a
Investors lower their expectations Our Logo
Barclays Cuts Price Target on Ligand Pharmaceuticals to $110 From $120, Maintains Overweight Rating MT
Roth Capital Boosts Price Target on Ligand Pharmaceuticals to $90 From $85, Maintains Buy Rating MT
HC Wainwright Adjusts Ligand Pharmaceuticals Price Target to $135 From $310, Maintains Buy Rating MT
Barclays Adjusts Price Target on Ligand Pharmaceuticals to $150 From $157, Reiterates Overweight Rating MT
Roth Capital Partners Cuts Price Target on Ligand Pharmaceuticals to $175 From $185, Reiterates Buy Rating MT
Barclays Adjusts Price Target on Ligand Pharmaceuticals to $157 From $165, Reiterates Overweight Rating MT
CJS Securities Adjusts Ligand Pharmaceuticals Price Target to $145 From $210, Maintains Market Outperform Rating MT
Stephens Adjusts Ligand Pharmaceuticals' Price Target to $130 from $153, Keeps Overweight Rating MT
Benchmark Adjusts Ligand Pharmaceuticals' Price Target to $130 From $180, Reiterates Buy Rating MT
LIGAND PHARMACEUTICALS INCORPORATED : Barclays Boosts Price Target on Ligand Pharmaceuticals to $180 From $174, Maintains Overweight Rating MT
LIGAND PHARMACEUTICALS INCORPORATED : Roth Capital Adjusts Price Target on Ligand Pharmaceuticals to $190 From $200, Maintains Buy Rating MT
LIGAND PHARMACEUTICALS INCORPORATED : Barclays Adjusts Price Target on Ligand Pharmaceuticals to $190 From $198, Maintains Overweight Rating MT
LIGAND PHARMACEUTICALS INCORPORATED : Stephens Reinstates Ligand Pharmaceuticals at Overweight With $200 Price Target MT
Treasury Markets Calm, But Investors Anticipate a Rate Rise Soon DJ
LIGAND PHARMACEUTICALS INCORPORATED : Barclays Adjusts Price Target on Ligand Pharmaceuticals to $198 From $146, Reiterates Overweight Rating MT
LIGAND PHARMACEUTICALS INCORPORATED : Craig-Hallum Adjusts Price Target on Ligand Pharmaceuticals to $215 From $195, Reiterates Buy Rating MT
LIGAND PHARMACEUTICALS INCORPORATED : Roth Capital Adjusts Price Target on Ligand Pharmaceuticals to $200 From $195, Maintains Buy Rating MT
LIGAND PHARMACEUTICALS INCORPORATED : HC Wainwright Adjusts Ligand Pharmaceuticals' Price Target to $310 From $299, Keeps Buy Rating MT
Berenberg USA Conference FA
Ligand Pharmaceuticals Incorporated to Receive $10 Million from a Contractually Specified Royalty Rate Buy-Down; Provides Financial Guidance for the Year 2017 CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
73.1 USD
Average target price
116.8 USD
Spread / Average Target
+59.78%
High Price Target
144 USD
Spread / Highest target
+96.99%
Low Price Target
95 USD
Spread / Lowest Target
+29.96%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Ligand Pharmaceuticals Incorporated

Barclays
Roth Capital Partners
HC Wainwright
CJS Securities
Stephens Inc.
Benchmark Capital
Craig-Hallum
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock Ligand Pharmaceuticals Incorporated - Nasdaq
  4. Consensus Ligand Pharmaceuticals Incorporated